Why Biomarker Results Define the NSCLC Treatment Path
Non-small cell lung cancer isn't one disease - it's several different types based on genetics. The right first treatment depends on which driver mutations or immune markers a patient's tumor has. For a clinic, biomarker results aren't just background. They drive your treatment decisions.
The three most important tests are EGFR mutation status, ALK rearrangement status, and PD-L1 tumor proportion score (TPS). Each points to a different treatment option. When results come back late or in the wrong format, treatment gets delayed.
This article explains what each test measures, what the results mean for treatment, and where clinic workflows usually break down.
EGFR Mutations: The Most Tested Driver in Adenocarcinoma
EGFR (epidermal growth factor receptor) mutations are the most common driver in adenocarcinoma. A systematic review found EGFR mutations in about 32% of all NSCLC cases, and in 38% of patients with adenocarcinoma specifically.
The two most common EGFR mutations are exon 19 deletions and the L858R point mutation in exon 21. These two account for most EGFR mutations you'll find. Less common variants, like exon 20 insertions, need different treatment and may not show up in older single-gene tests.
How you test matters. PCR-based assays find common mutations quickly but can miss rare ones. Next-generation sequencing (NGS) panels find all mutations, including extra mutations that can change treatment options. Many guidelines now recommend NGS as the standard test for newly diagnosed adenocarcinoma to avoid having to redo the biopsy if you find a rare mutation later.
In the clinic, an EGFR-positive result starts a specific workflow: the team documents the variant, checks for other mutations, and plans a targeted therapy talk. This talk can't happen until results arrive, which makes how fast you get results a clinical issue, not just a lab matter.
ALK Rearrangements: Low Prevalence, High Clinical Consequence
ALK (anaplastic lymphoma kinase) rearrangements show up in fewer cases than EGFR mutations. A 2025 NSCLC update counts ALK rearrangement as a defined driver. Even though it's not as common, finding it - or missing it - is very important.
ALK-positive tumors show up more in younger patients and non-smokers. But don't skip testing based on age or smoking status. ASCO and CAP guidelines say all patients with advanced adenocarcinoma should get full biomarker testing no matter their age or smoking history. Limiting testing based on who the patient is can mean missing a finding you could actually treat.
Three methods find ALK rearrangement: fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and NGS-based fusion detection. FISH was the standard for years, but IHC with good antibodies and NGS panels work just as well in good labs. The choice usually depends on available tissue and lab equipment, not differences in how well they work.
In practice, ALK testing is ordered at the same time as EGFR and PD-L1, not one after another. Testing one marker at a time uses up limited biopsy material and slows down results. Testing everything together saves tissue and speeds up the final results.
PD-L1 Tumor Proportion Score: The Immunotherapy Gatekeeper
PD-L1 (programmed death-ligand 1) expression is measured as a tumor proportion score (TPS) to predict if a patient's tumor will respond to checkpoint inhibitor therapy. Different PD-L1 scores - less than 1%, 1-49%, and 50% or higher - point to different treatment options.
PD-L1 is an IHC test done on the biopsy. It's faster than NGS and usually comes back in a few days. But PD-L1 results don't stand alone. In a patient with an EGFR mutation or ALK rearrangement, the PD-L1 score is reviewed with driver mutation status. Checkpoint inhibitor alone doesn't work well for EGFR- or ALK-positive disease.
This matters for workflow. A clinic that gets a high PD-L1 score while waiting for EGFR results may feel pressure to start treatment. But acting on PD-L1 alone, before EGFR results come back, can push you down the wrong path. Getting all three results before the treatment talk is a real challenge in community and academic centers.
The Turnaround Time Problem in Real Clinics
It takes longer to get all biomarker results back than doctors want. A Canadian study found that it took 26 days from diagnosis to the first NGS result, compared with 15 days for other tests. At the first oncology visit, only 20% of patients had all results ready.
This gap costs time. Patients who had all results at their first visit started treatment in 16 days. Patients who didn't had to wait 29 days. That 13-day gap comes mostly from how the clinic is organized, not from the disease itself.
In a busy clinic, delays pile up across all active patients. Tracking who's waiting on what results, and flagging patients nearing dangerous wait times, needs a real system, not just chart reviews.
Building a Workflow That Closes the Gaps
Most improvements to NSCLC biomarker workflows come from three changes: reflex ordering, testing everything at once instead of one at a time, and centralized result tracking.
Reflex ordering means the pathologist orders all tests when the biopsy comes in, without waiting for the oncologist to ask. This removes one handoff and can cut several days off total time. Testing EGFR, ALK, and PD-L1 at the same time on one sample saves tissue and avoids the delays that come from testing one at a time. CAP and ASCO guidelines support both of these practices for advanced adenocarcinoma.
Centralized result tracking is how software solves this problem. When a biomarker result lands in the lab system, it needs to show up in the oncologist's workflow when it counts, not lost in email. When results are formatted right with alerts tied to appointment dates, doctors see them before the visit instead of during it.
Structured lab result feeds pull biomarker results from reports and link them to each patient. A good system shows you at a glance which results are waiting, which have arrived, and whether a new PD-L1 score conflicts with pending EGFR results. For more on how AI can extract and structure these results, see From PDFs to patient insights: how AI lab extraction changes clinical routine.
On the scheduling side, result status should drive appointment timing. Scheduling a treatment talk before EGFR results come back wastes time. Aligning appointment bookings with when results are expected helps the whole team work better. For more on structuring oncology appointments around clinical milestones, see Why oncology clinics need treatment timelines, not just calendars.
What Clinic Teams Can Act On Now
Review these questions with your pathology and oncology teams:
- Does your clinic use reflex biomarker ordering for newly diagnosed adenocarcinoma, or does testing depend on a separate oncologist order?
- Are EGFR, ALK, and PD-L1 tested at the same time on one sample, or one at a time?
- What is your median NGS turnaround time, and how does that align with scheduled first consultation dates?
- How does your team track pending biomarker results across all active patients?
- Are high PD-L1 scores flagged for clinical review alongside pending EGFR or ALK results before a treatment decision is made?
These are process audit points. They separate clinics with good coordination from those with avoidable delays.